VRTX - Amicus shares rise on acquisition speculation from Vertex

Amicus Therapeutics (FOLD) share are up 6.7% in morning trading after a Dealreporter piece speculated it may be a takeout target for Vertex (VRTX).The article also points out Biomarin (BMRN) could be a Vertex acquisition target, though shares of that company are down 0.3% right now.THE Dealreporter piece notes, "We have previously highlighted Amicus Therapeutics...as a potential name to keep an eye on, given VRTX's previous interest in the gene therapy space.Separately, Amicus filed an automatic shelf registration with the SEC for the resale of up to 2,554,999 underlying warrants to purchase shares.Amicus filed an SEC Form S-3 shelf offering on Jan. 29, but then amended it on Feb. 2 due to a filing error.Maximum aggregate offering price is $48.9M.Amicus shares were up 6.7% to $20.53 in morning trading.

For further details see:

Amicus shares rise on acquisition speculation from Vertex